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ABSTRACT 
Background: Alcohol consumption has been comprehensively investigated as an etiologic 
risk factor for breast cancer but has received little attention in terms of its impact on 
prognosis after breast cancer, particularly for young women. 
Methods: 1286 women diagnosed with invasive breast cancer at or before 45 years of age 
from two population-based case-control studies in the Seattle-Puget Sound region were 
followed from their diagnosis of breast cancer (between January 1983 and December 
1992) for survival through June 2002, during which time 364 women had died. Cox 
proportional hazards modeling was used to assess the effect of pre-diagnostic alcohol 
consumption on the risk of dying. 
Results: After adjusting for age and diagnosis year, compared to non-drinkers, women 
who consumed alcohol in the 5 years prior to diagnosis had a decreased risk of death [>0 
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to <3 drinks per week: HR(hazard ratio) = 0.7 (95% CI: 0.6-0.95); 3 to <7 drinks per 
week: RR = 0.6 (95% CI: 0.4-0.8); ≥ 7 drinks per week: RR = 0.7 (95% CI: 0.5-0.9)]. 
This association was unchanged upon additional adjustment for potential confounders 
including most notably treatment, stage at diagnosis, and mammogram history.   
Conclusion: These results suggest that women who consume alcohol prior to a diagnosis 
of breast cancer have improved survival which does not appear to be attributable to 
differences in stage, screening or treatment. 
 
INTRODUCTION 
While alcohol consumption has been identified as one of the few, known 
modifiable risk factors for breast cancer,2;17;22;34;42 its possible role in breast cancer 
recurrence and mortality has received little research attention, particularly in younger 
women.  Light to moderate amounts of alcohol consumption have been associated with 
lower overall and coronary heart disease-associated mortality among women.11;36 
However, evidence has been sparse and inconsistent for the effect of alcohol 
consumption on breast cancer mortality in young women.14;24;29 
There is an indication that alcohol’s effects may take place during late breast 
carcinogenesis due to the association between alcohol consumption and late stage breast 
cancer and lack of association between alcohol and benign proliferative epithelial 
disorders of the breast.33;38   Prior etiologic studies have shown that the most relevant 
timing of exposure for certain exogenous risk factors for breast cancer, including alcohol, 
may be the years immediately preceding diagnosis.21;30;35  Furthermore, in a meta-
analysis of 38 studies investigating alcohol consumption and breast cancer risk, 
Longnecker describes the finding that cohort studies with longer follow-up time showed 
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weaker effects of alcohol use on breast cancer incidence indicating that the salient time 
period for alcohol use was recent use.22   
 Given the consistent nature of the association of alcohol and breast cancer risk as 
well as the common nature of alcohol consumption, we evaluated the effect of pre-
diagnostic alcohol consumption on the risk of death (overall and breast cancer mortality) 
in a population-based cohort study of breast cancer patients diagnosed before 45 years of 
age, focusing primarily on recent use of alcohol. 
 
MATERIALS AND METHODS 
Study population 
The 1,286 women with invasive breast cancer in the current study were drawn 
from two previously completed population-based case-control studies of breast 
carcinoma conducted at the Fred Hutchinson Cancer Research Center.  The methods for 
both studies were essentially the same and have been described previously.1;6  The cases 
were identified from the Cancer Surveillance System (CSS) which is part of the 
Surveillance, Epidemiology, and End Results (SEER) Program, with eligibility criteria 
for the first study including: first primary breast carcinoma diagnosis between January 
1983 and April 30, 1990; diagnosed before age 45; women born after 1944; women of 
Caucasian race.  Interviews were completed on 845 women (83.3% of eligible cases).  In 
the second study, cases were also identified through CSS with eligibility criteria 
including: first primary breast carcinoma identified from May 1, 1990 through December 
31, 1992; diagnosed before age 45; women of any race were included.  643 women 
(83.9% of eligible cases) were interviewed as part of this study.   
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In-person interviews conducted through these previous studies included questions 
ascertaining lifetime history of a variety of known and suspected breast cancer risk 
factors including pre-diagnostic history of alcohol consumption and smoking, body size 
history, and reproductive risk factors.  With regard to alcohol use, participants were asked 
about their volume (number of drinks), frequency (times per day/week/month) and type 
(beer/wine/liquor) of alcohol use from the time alcohol use began until their diagnosis of 
breast cancer. Participants self-defined the relevant time spans for the various patterns of 
consumption of each type of beverage throughout their lives. This study’s protocol was 
approved by the Institutional Review Board of the Fred Hutchinson Cancer Research 
Center. 
 
Follow-up 
The methods used to follow up the breast carcinoma cases have been reported 
previously and are summarized only briefly here.5  Active (i.e. hospital and physician 
annual follow-up) and passive (i.e. National Death Index) surveillance of vital status of 
study participants was performed by CSS.  For women whose cause of death was 
unavailable through the CSS, death certificates were obtained and causes of death were 
classified as breast cancer related or not using the CSS protocol. Participants underwent 
follow-up until the earliest of the date of death, the date last known to be alive, or the end 
date of our follow-up period (June 2002).  Among those not reported to be dead, 93.1% 
had been contacted within 12 months of the end of the follow-up period. 
The primary mortality end point used was all-cause mortality. In this age group, 
deaths from other causes are fairly minimal and the vast majority of deaths were related 
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to breast cancer.  Of 364 deaths, 335 (92.0%) were known to be due to breast carcinoma, 
22 (6.0%) were due to other causes, and 7 (1.9%) were unknown as to the cause of death.  
Analyses were repeated using breast cancer death as the mortality end point and 
censoring women with other causes of death at the time of their death and results were 
unchanged (see Results section).  
 
Pathology review, testing of tumor samples for prognostic markers, and collection of 
treatment information 
Tumor specimens were available for a centralized pathology review on 1019 
(79.2%) of the 1286 breast cancer cases.  For the remaining samples, either permission 
was not given to access the tumor tissues, or tumor blocks were not available or had been 
discarded by the laboratories.  907 (70.5%) cases had adequate tissue samples available 
for immunoperoxidase assays.  Tumors were evaluated for expression of estrogen 
receptor (ER), progesterone receptor (PR), p53 tumor suppression gene protein, Ki-67 
proliferation-related antigen, c-erb B-2 oncogene protein, apoptosis regulatory protein 
bcl-2, cyclin E protein, s-phase fraction, and p27 protein, as previously described.4;12 
Tumors were classified as positive/high staining or negative/low staining based on the 
percentage of tumor cells staining positive and/or the pathologist’s interpretation of 
staining intensity.  For ER, PR and p53, any nuclear staining was considered positive; the 
percentage of Ki-67 was averaged over four high-power fields with ≥ 25% considered 
high proliferation; for tumor necrosis factor, categories of none and intermediate were 
combined vs. high; for bcl-2, negative and low-intensity stains were categorized as low, 
while intermediate and high-intensity stains were categorized as high. 
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Women whose tumors were available for analysis were on the whole similar to 
the women without tumor data available, with the exception that women with available 
tumor samples were older at diagnosis (80.1% were 35 years and older) than the women 
without tumor samples (72.3% [p = 0.006]).  There were no apparent differences in 
alcohol consumption or mortality between women whose tumor samples were and were 
not available for analyses (p = 0.20, and 0.32, respectively).  
Medical records were abstracted to identify courses of treatment including 
surgery, radiation therapy, chemotherapy, and/or hormonal therapy.  1,113 cases (86.5%) 
included in this analysis had their medical record reviewed by trained medical record 
abstractors.  For those participants who refused medical record review, whose records 
were destroyed, or who had incomplete information with respect to treatment, treatment 
information was obtained from the follow-up study questionnaires and the CSS.  
 
Statistical Analysis: 
For the primary analysis focused on recent alcohol consumption, the average 
weekly alcohol consumption was computed for the period spanning 7 years to 2 years 
prior to diagnosis.  To compute the weekly average number of drinks consumed over this 
time period, we calculated the total number of drinks consumed during the period 
(summing over all applicable episodes reported) and divided by 260, the total number of 
weeks in the 5-year period.   
Average weekly alcohol consumption was categorized as never or none during 
this period, >0 to <3, 3 to <7, and 7 or more drinks per week; from this point forward, we 
refer to these categories as non-drinkers, light, moderate, and heavy drinkers, 
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respectively. A woman who had consumed less than 12 alcoholic beverages in her 
lifetime or less than one drink per month for 6 months or more was considered a never 
drinker.  Alcohol consumption during the two year period immediately preceding 
diagnosis was omitted from computations in order to exclude any disease-related changes 
in alcohol consumption.35  For the sake of brevity, we will henceforth refer to the 7 to 2 
years before diagnosis as the 5 years prior to diagnosis.   
The lifetime average weekly intake of alcohol was determined by calculating the 
average amount of alcohol consumed per week from age 15 until diagnosis. We also 
investigated alcohol exposure by beverage type: wine, liquor, and beer.  One drink was 
defined as 12 oz of beer, 1.5 oz liquor, and 4 oz wine. 
Estimates of the relative risk of dying were calculated using Cox proportional 
hazards models.  The hazard ratios (HR) were left-truncated to account for the time lag 
between diagnosis and interview.  Censoring occurred at either the date of last known 
follow-up or the end date of follow-up (June 2002) if death had not occurred prior to this.  
Interaction terms were investigated using the likelihood ratio test (LRT). 
Age and reference year were accounted for in all analyses. We assessed the 
following factors for their potential confounding or modifying effects: mammogram 
history (defined as ever having a mammogram), smoking history (never, former, current), 
body mass index (quartiles), education (<high school, high school/some college, 
graduated college), income (<$15,000/year, $15,000 to $50,000/year, >$50,000/year), 
race (Caucasian, African American, Asian, and other) and OC use (never use, < 10 years 
of OC use, 10 or more years of use).   
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The Mantel-Haenszel Chi-Square test was used for all bivariate anlayses.  To be 
included as a potential confounder in the multivariate analysis, we required that a variable 
be associated with both alcohol consumption and the outcome.  Variables which altered 
the estimate in the multivariate model by 10% or more were retained in the final model. 
The variables meeting these criteria within the Cox proportional hazards model were age 
and year of diagnosis, and mammogram history.   
We examined the association between alcohol consumption and tumor 
characteristics using logistic regression to assess the odds of breast cancer with specific 
tumor characteristics, and reported odds ratios (ORs) and 95% CIs.  An investigation into 
the potential confounding factors involved in this analysis indicated that age at diagnosis, 
diagnosis year, and smoking history all met the criteria, as set forth above, for 
confounding, and thus were included in the logistic regression model.   
 
RESULTS 
The association between mortality and demographic features and tumor 
characteristics is shown in Table 1.  Women diagnosed before 1989 had a greater risk of 
dying; women reporting a history of a prior screening mammogram had a reduced risk of 
dying.  As would be expected, tumor characteristics known to be unfavorable, including 
larger tumor size, later stage at diagnosis, and positive nodal status, were all associated 
with an increased risk of mortality in this cohort.  As previously shown in this dataset, the 
highest quartile of BMI (≥25.8 kg/m2) was associated with an increased risk of mortality 
compared to the first quartile (≤20.6 kg/m2); the recency of pregnancy increased the risk 
of mortality compared to nulliparous women; women with a first or second degree 
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relative with breast cancer were at a lower risk of mortality compared to women with no 
family history.4;5;23  Higher income (≥ $50,000/year) was associated with reduced 
mortality compared to income of less than $15,000/year. However, education was not 
associated with mortality.  Compared to White women, Black women were found to be at 
increased risk of mortality while Asian women were not. 
Factors associated with mortality after breast cancer were examined for their 
relationship with alcohol consumption in the five year period before diagnosis (Table 2). 
Most of these factors varied significantly by alcohol consumption status, including age at 
diagnosis, mammogram history, history of OC use, diagnosis year, race, smoking status, 
and quartile of BMI. 
Compared to women who reported no alcohol consumption in the five year period 
before diagnosis, women who consumed alcohol during the same interval had a 30% 
reduction in the risk of dying after breast cancer (0.7 [95% CI, 0.5-0.9]; Table 3).  This 
reduction in the risk of dying did not vary substantively on the basis of the average 
number of drinks consumed [compared to non-drinkers, the risk of death for light 
drinkers was 0.7 (95% CI, 0.6-0.95); for moderate drinkers was 0.6 (95% CI, 0.4-0.8); for 
heavy drinkers was 0.7 (95% CI, 0.5-0.9)]. We found similar patterns of risk in relation to 
average lifetime alcohol consumption.   
These and all other hazard ratios reported henceforth were adjusted for age, 
diagnosis year, and mammography. The association between recent alcohol consumption 
and the risk of dying was not altered by adjustment for any additional potential 
confounders.  Further, adjustment for factors related to mortality, namely stage, 
histologic grade, and treatment factors, did not change results (compared to non-drinkers, 
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HR = 0.7 [95% CI, 0.5-0.9] for light drinkers; 0.5 [95% CI, 0.3-0.7] for moderate 
drinkers; and 0.6 [95% CI, 0.4-0.8] for heavy drinkers).  Also, there was no evidence of 
significant effect modification by BMI, smoking, or age. 
Further examination by beverage type revealed that this reduction in risk of dying 
associated with recent alcohol consumption was limited to wine consumption (RR= 0.7 
[95% CI, 0.6-0.9]).  These results were unchanged when adjusted for beer and liquor 
drinking. There was no association observed with beer or liquor consumption (Table 3).   
To assess possible mechanisms underlying the association between alcohol and 
improved survival, we examined the relationship of recent alcohol consumption to 
selected tumor characteristics that are markers of adverse prognosis. Alcohol 
consumption was unrelated to ER or PR status, BCL-2 expression, stage, or percentage of 
tumor cells in s-phase (Table 4).  Alcohol consumption was related to a reduced odds of 
having a tumor with high tumor necrosis levels (OR =0.6 [0.4-0.98]) and marginally to 
p53 positive tumors (OR = 0.7 [95% CI: 0.5-1.0]).     
Including p53 and tumor necrosis in the Cox model for recent alcohol use did not 
affect the significance of the association for moderate (HR=0.5 [95% CI, 0.3-0.8]) or 
heavy drinkers (HR=0.7 [95% CI, 0.5-0.98]), but did affect the statistical significance for 
light drinkers (0.8 [95% CI, 0.6-1.1]). 
Finally, we examined our main results to assess variation according to several 
sources of effect modification or bias. Results were similar to those reported above when 
analyses were restricted to premenopausal women (compared to non-drinkers, HR = 0.7 
[95% CI, 0.6-0.96] for light drinkers; 0.5 [95% CI, 0.4-0.8] for moderate drinkers; and 
0.7 [95% CI, 0.5-0.95] for heavy drinkers).  Results were also unchanged when we 
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restricted to deaths due to breast cancer (excluding the small number of non-breast cancer 
related deaths; HR = 0.7 [95% CI, 0.6-0.97] for light drinkers; HR = 0.6 [95% CI, 0.4-
0.9] for moderate drinkers; HR = 0.7 [95% CI, 0.5-0.9] for heavy drinkers).  
Additionally, because this study retrospectively ascertained breast cancer cases in 1983 – 
1985, we repeated analyses excluding cases diagnosed before 1986 and again found our 
results were unchanged (HR = 0.7 [95% CI, 0.6-0.96] for light drinkers; 0.6 [95% CI, 
0.4-0.8] for moderate drinkers; and 0.6 [95% CI, 0.5-0.9] for heavy drinkers).   Also, as 
this analysis combined two study populations, we conducted the analysis separately 
within each study and found similar results in each study, although individually these 
results lack the same precision as found in the combined analysis due to the smaller 
sample sizes (in the study conducted with women diagnosed from 1983 to 1990, HR = 
0.8 [95% CI, 0.6-1.1] for light drinkers; 0.6 [95% CI, 0.4-0.96] for moderate drinkers; 
and 0.8 [95% CI, 0.5-1.1] for heavy drinkers; in the study conducted with women 
diagnosed from 1990-1992, HR = 0.7 [95% CI, 0.5-1.0] for light drinkers; 0.5 [95% CI, 
0.3-0.95] for moderate drinkers; and 0.6 [95% CI, 0.3-1.0] for heavy drinkers).  Lastly, in 
analyses restricted to women with available tumors, the results were unchanged (HR = 
0.7 [95% CI, 0.6-0.97] for light drinkers; 0.5 [95% CI, 0.3-0.7] for moderate drinkers; 
and 0.6 [95% CI, 0.5-0.9] for heavy drinkers). 
 
DISCUSSION 
In the interpretation of the above findings, we should consider the limitations of 
our study.  First, we were unable to interview 15% of the women eligible for the original 
case-control studies on which this population-based cohort study was based.  At five 
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years, 43.5% of the non-interviewed cases and 14.5% of the interviewed cases were 
deceased.  To the extent that non-interviewed cases differ from interviewed cases on the 
basis of their alcohol consumption, our results may be biased.  Because this differential 
was greatest for women in the earliest years of the cohort (due to a lag in interviewing), 
we assessed its potential impact through a subset analysis limited to women diagnosed 
after 1986.  The absence of any change in results suggests that our results may be 
generalizable to the entire spectrum of breast cancer cases.  A second potential limitation 
was the possibility of confounding.  Despite the breadth of data available to us to assess 
potential confounding influences, including comprehensive treatment data and other 
lifestyle variables, we could not exclude the possibility of unmeasured or residual 
confounding that accounts for our findings.  Additionally, this study did not collect 
information on dietary factors, and as a result, we were unable to examine whether 
dietary factors may modify the effect of alcohol consumption on risk of death.  Also, 
since this study was performed in a sample of predominantly white women, reflecting to 
a great extent the underlying racial distribution of the Seattle-Puget Sound area, we 
cannot be sure these results are generalizable to non-white populations.  Lastly, the 
ascertainment of alcohol exposure relied on self-reported drinking history.  The 
interviewer-guided questionnaires were developed to chart the pattern of exposure 
beginning with the age at which alcohol consumption began and document the changes in 
this pattern over time.  Overall, the quantity/frequency method for ascertaining alcohol 
exposure is a reliable approach to estimate alcohol use and the accompanying strategy of 
using a lifetime calendar with milestones noted further facilitated recall.7 In our analysis, 
we found an effect achieved by any intake of alcohol and the magnitude of this 
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association did not vary further according to levels of alcohol consumption, and thus 
misclassification within different categories of use would have minimal impact on the 
interpretation of our results. Because any misclassification resulting from this is likely to 
be non-differential, misclassification in this case would lead to an attenuation of the real 
effect of alcohol in our results. 
The strengths of this study are also worth noting, including the population-based 
design which heightens the generalizability of the results, the large sample size, 
particularly the large numbers of very young cases, and the centralized pathological 
review and lab analyses performed on tissue samples.   
Our results indicate that young women who consumed alcohol prior to a diagnosis 
of breast carcinoma were at a decreased risk of mortality compared to women who 
consumed no alcohol.  There was some suggestion that the decreased risk of death was 
limited to wine consumption.  This reduction in risk of dying does not appear to be due to 
differences in mammography screening history, tumor characteristics, treatment, or other 
exposures.  
Little research has been focused on the association between alcohol and risk of 
dying after a breast cancer diagnosis, particularly among young women. A number of 
studies have found results broadly similar to ours in terms of the direction and magnitude 
of effects although in general these studies represent an older demographic than ours.  In 
Saxe, et al, while the risk of death among premenopausal breast cancer cases associated 
with alcohol consumption did not reach statistical significance (HR = 0.41 [0.01-16.35] 
per 2 drinks/day), the magnitude of the observed effect was consistent with our findings.  
Their sample of 149 breast cancer patients consisted of 51 (34.2%) premenopausal and 98 
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(65.8%) postmenopausal women with a median age of 57.8 (in our study, 92.5% were 
premenopausal).  Similarly, Holmes, et al, observed a decreased risk of death among 
breast cancer cases in relation to prior alcohol consumption in the Nurses’ Health Study. 
However, these results also failed to reach statistical significance (HR=0.79 [0.61-1.02], 
0.86 [0.63-1.16], and 0.92 [0.66-1.27] for the second, third, and fourth quartiles, 
respectively, compared to the first quartile of alcohol consumption).15  While this study 
had a generous sample size of 1,982 women with invasive breast cancer, it reflected a 
wider age spectrum and older age group than ours, with a mean age of 54 years (versus 
our study’s 37.7).   Lastly, Zhang, et al, observed a non-statistically significant reduction 
in risk of death for women consuming 4 grams or more of alcohol per day (risk of death 
0.7 [0.3-1.5]) in a dataset of 698 breast cancer patients aged 55-69 years at baseline.40  
Some studies with results which conflict with ours include Hebert, et al, who 
observed in their hospital-based cohort of 546 early-stage breast cancer cases that beer  
(but not wine or liquor) consumption was related to an increased risk of breast cancer 
mortality among pre-menopausal women.14  McDonald, et al, in a hospital-based cohort 
of 125 post-menopausal African American breast cancer cases, found pre-diagnostic 
consumption of at least one drink per week was associated with a 2.7 times greater risk of 
all-cause mortality.25  The inconsistencies in these epidemiologic studies, as a whole, 
potentially reflect the heterogeneity of alcohol as an exposure and the relatively small 
samples of breast cancer patients that have been studied in many of these analyses.  
Additionally, there is reason to believe that pre-menopausal and post-menopausal breast 
cancer development differs,27 and thus potentially alcohol’s impact on tumorigenesis 
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differs among pre- and post-menopausal women which would create inconsistencies 
across studies with different age ranges.    
Previous studies have not investigated the role of pre-diagnostic alcohol use on 
tumor characteristics in young women.  Our data indicate that alcohol’s role in decreasing 
the risk of death among breast cancer death may be through its effect on reducing the risk 
of p53 positive tumors and tumors with high necrosis levels, both of which are associated 
with decreased survival. However, adjusting for these factors did not fully explain the 
association of alcohol with improved mortality, particularly in moderate and heavy 
drinkers. 
A potential mechanism involving alcohol consumption in breast cancer survival 
includes the role of genes involved in metabolism of drugs and other toxins, such as the 
cytochrome P450 and glutathione S-transferase enzymes.  Some of the women who chose 
not to drink may have a deficiency in their metabolism of alcohol causing their bodies to 
react unfavorably to the ingestion of alcohol; this same subset of women could also 
experience poor metabolism of chemotherapeutic agents based on poor drug metabolism, 
resulting in higher toxicity to typical doses. This mechanism would require the genes 
involved in alcohol metabolism to be the same genes involved in chemotherapy 
metabolism.  Some support for the hypothesis that chemotherapy and alcohol metabolism 
operate in a shared pathway is the observation that alcohol and certain chemotherapeutic 
agents, including methotrexate and 5-fluorouracil, are involved in the folate pathway. 
8;37;41   
Interestingly, several studies have shown an interaction between folate and 
alcohol in breast cancer, indicating that the effect of alcohol on breast cancer incidence 
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may be reduced by dietary folate.31;41  The role of folate in breast cancer development is 
complex with indications that folate has a dual nature in tumorigenesis involving 
mechanisms that are anti- and pro- carcinogenic depending on the timing and dose of 
folate.18-20  In breast cancer development, a hypothesis involving folate and alcohol could 
include folate’s anti-carcinogenic (e.g. DNA repair capabilities) properties being 
diminished by alcohol consumption which is compatible with the increased breast cancer 
risk associated with low folate levels occurring only among regular alcohol drinkers.31 
However, with regard to survival from breast cancer, it is less clear how folate and 
alcohol would interact.  Perhaps, alcohol diminishes the amount of folate available, and 
thus the pro-carcinogenic properties (e.g. increased proliferation) of folate that are 
proposed to occur later in tumor development are diminished, which is consistent with 
the timing of alcohol’s effects as suggested to occur later in tumorigenesis.  This would 
be compatible with the finding in our data that alcohol consumption did not lead to 
tumors with high proliferation, as indicated by the Ki-67 index, however, we were unable 
to directly test a mechanism involving folate because our study did not collect 
information on dietary factors.  
Current hypotheses regarding alcohol’s role in breast cancer etiology include the 
effect of alcohol on circulating hormone levels.33  Recent findings from the Epic Cohort 
showed that levels of dehydroepiandrosterone (DHEAS), free testosterone, and estrone 
increase as alcohol consumption increases in pre- and post-menopausal women. However 
no statistically significant increase was observed for estradiol, free estradiol, or sex 
hormone binding globulin (SHBG) in response to increasing alcohol consumption in 
premenopausal women.28  Additionally, alcohol has been shown to increase proliferation 
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in ER+, but not ER-, breast cancer cell lines.32  Our data did not provide support for the 
role of alcohol in breast cancer survival to involve hormones in that there were no clear 
associations with hormone-related tumor markers. This would make sense if alcohol acts 
later in tumorigenesis when some of the tumor features, such as ER/PR status, have 
already been established.  
Additionally, a hypothesis involving insulin-like growth factor (IGF) has been 
developed to explain the increased risk of breast cancer associated with alcohol 
consumption.9  In response to the observation that breast cancer risk did not increase 
further within the highest level of alcohol consumption,34;41 Hu hypothesized that IGF 
levels decrease as a result of impaired liver function due to high consumption of 
alcohol.39;41  With the observation that breast cancer risk was associated with high serum 
levels of IGF in pre-menopausal women,13 Jones and Clemmons put forth a mechanism 
for IGF’s role in carcinogenesis involving IGF’s mitogenic effects and suppression of 
apoptosis, which counteracts the role of wildtype p53 protein.16  It is possible that plasma 
IGF levels, as mediated by alcohol, are reduced and thus, the role of the wildtype p53 
protein is more pronounced in tumorigenesis among women who consume alcohol; 
therefore, (and as our data suggests) variant p53 would play a greater role proportionately 
in the tumors of alcohol drinkers.   
Also, with the suggestion in our results that wine, but not beer or liquor, may 
reduce the risk of death among breast cancer patients, we speculate that components of 
wine such as polyphenols, (e.g. reservatrol and cinnamic acid) could be contributory 
factors.  Several long-term epidemiologic cohort studies have demonstrated that wine is 
associated with a decreased overall mortality, and that the effect is not as strong or not 
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observed at all in drinkers of beer or liquor.26  Research investigating the protective 
effects of wine has mostly centered around mechanisms involved in cardiovascular 
disease, including the antioxidant effects of polyphenols.3;10  In cancer it is possible that 
the antioxidant properties of wine’s components have a role in decreasing the process of 
tumorigenesis, although their role in survival would be less clear.  Perhaps in breast 
cancer, the pathway leading to p53-negative tumors and low necrosis levels in tumors are 
mediated by polyphenol’s antioxidant effects.  
While alcohol may increase the risk of developing breast cancer in young women, 
2;17;22;42 an age group where tumors tend to be aggressive and mortality is high, it does not 
appear to have an adverse effect on progression.  The results from this study suggest that 
women who consume alcohol prior to a diagnosis of breast cancer have improved 
survival compared to non-drinkers which does not appear to be attributable to differences 
in stage, screening, treatment or other confounders.  Our results do not exclude the 
possibility that abstainers are at an increased risk of death due to the potential clustering 
of confounders for which we were unable to adjust, and may be separate from the 
biologic pathways, such as inability to metabolize alcohol adequately, we discussed 
above.  The findings presented here need to be replicated in similar study populations 
with an emphasis on elucidating mechanisms.     
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TABLES  
Table 1. Relationship of Demographic and Tumor Characteristics to the Risk of Dying among 
Women Diagnosed with Breast Cancer under 45 Years of Age from 1983 to 1992 
 
   Alive Dead HR1 95% CI 
    
Age at 
diagnosis 
< 35 179 (65.1) 96 (34.9) 1.0  
≥ 35 743 (73.5) 268 (26.5) 0.9 0.7 1.1 
    
Diagnosis Year < 1989 358 (65.3) 190 (34.7) 1.0 (ref)  
≥ 1989 564 (76.4) 174 (23.6) 0.8* 0.6 1.0** 
    
Ever use of 
Mammogram2 
No 506 (67.1) 248 (32.9) 1.0 (ref)  
Yes 416 (78.2) 116 (21.8) 0.7* 0.6 0.9 
    
Chemotherapy3 No 299 (75.3) 98 (24.7) 1.0 (ref)  
 Yes 617 (70.0) 264 (30.0) 0.9 0.7 1.1 
    
Radiotherapy3 No 414 (70.2) 176 (29.8) 1.0 (ref)  
 Yes 502 (73.0) 186 (27.0) 0.9 0.7 1.1 
    
Hormone 
Therapy 
No 551 (71.0) 225 (29.0) 1.0 (ref)  
Yes 300 (70.9) 123 (29.1) 1.0 0.9 1.0 
    
Stage Local 608 (82.5) 129 (17.5) 1.0 (ref)  
 Regional 304 (59.6) 206 (40.4) 2.6* 2.1 3.2 
 Distant 1 (4.0) 24 (96.0) 22.0* 14.0 34.4 
    
Tumor Size ≤ 2 cm 527 (80.6) 127 (19.4)  1.0(ref)  
 >2 – 5 cm 326 (65.3) 173 (34.7) 1.9* 1.5 2.4 
 > 5 cm 51 (50.0) 51 (50.0) 3.0* 2.2 4.2 
    
Nodal Status Negative 615 (82.3) 132 (17.7) 1.0 (ref)  
 Positive 302 (56.0) 219 (42.0) 1.5* 1.4 1.6 
    
BMI 1st quartile 241 (75.6) 78 (24.4) 1.0 (ref)  
 2nd 230 (72.8) 86 (27.2) 1.1 0.8 1.6 
 3rd 238 (74.3) 82 (25.6) 1.2 0.9 1.6 
 4th  205 (63.9) 116 (36.1) 1.9* 1.4 2.5 
    
Recency of 
Pregnancy 
Nulliparous 251 (74.9) 84 (25.1 1.0 (ref)  
5+ yrs 529 (74.0) 186 (26.0) 1.1 0.8 1.4 
 2 - < 5 yrs 97 (67.8) 46 (32.2) 1.3 0.9 1.9 
 < 2 yrs 45 (48.9) 47 (51.1) 2.2* 1.5 3.0 
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1st or 2nd degree 
relative with 
breast cancer 
No  359 (69.2) 160 (30.8) 1.0 (ref)  
Yes 401 (75.8) 128 (24.2) 0.8* 0.6 1.0** 
    
    
Smoking Never 464 (71.1) 189 (28.9) 1.0 (ref)  
 Former 205 (73.5) 74 (26.5) 0.9 0.7 1.2 
 Current 253 (71.5) 101 (28.5) 1.0 0.8 1.2 
    
Race White 874 (71.8) 344 (28.2) 1.0 (ref)  
 Black 12 (54.6) 10 (45.4) 2.4* 1.2 4.5 
 Asian/Pac Isl. 31 (77.5) 9 (22.5) 1.0 0.5 2.0 
    
Income <15,000 85 (65.9) 44 (34.1) 1.0 (ref)  
 15000-50000 483 (69.1) 216 (30.9) 0.9 0.7 1.3 
 ≥ 50000 349 (77.7) 100 (22.3) 0.7* 0.5 1.0** 
    
Education < High 
   School 
30 (71.4) 12 (28.6) 1.0 (ref)  
 High School/ 
   Some 
   College 
560 (71.0) 229 (29.0) 1.2 0.7 2.2 
 College 
   Graduate 
332 (73.0) 123 (27.0) 1.2 0.6 2.1 
* statistically significant HR 
** 1.0 due to rounding, CI excludes 1.0 
 1 adjusted for age, mammogram, and diagnosis year, except as noted  
2 adjusted for age and diagnosis year 
3 adjusted for age, diagnosis year, nodal status, stage, and tumor size   
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Table 2. Relationship between Alcohol Consumption and Factors Observed to Influence the Risk 
of Dying among Women Diagnosed with Breast Cancer under 45 Years of Age from 1983 to 
1992 
   Alcohol consumption status in the 
5 years prior to diagnosis
   Non-Drinker1 Drinker p-value
    
Age at diagnosis < 35 50 (18.2) 224 (81.8) 0.002 
≥ 35 274 (27.1) 736 (72.9)  
    
Ever had a 
Mammogram  
No 175 (23.2) 579 (76.8) 0.046 
Yes 149 (28.1) 381 (71.9)  
    
OC use Never 99 (34.1) 191 (65.9) <0.0001 
 < 10 yrs 199 (24.3) 621 (75.7)  
 ≥10 yrs 26 (14.9) 148 (85.1)  
    
Diagnosis Year < 1989 93 (17.0) 454 (83.0) <0.0001 
≥ 1989 231 (31.3) 506 (68.7)  
    
Race White 287 (23.6) 929 (76.4) <0.0001 
 Black 12 (54.6) 10 (45.4)  
 Asian/Pac Islander 23 (57.5) 17 (42.5)  
    
Education < High School 12 (28.6) 30 (71.4) 0.29 
 High School / Some College 205 (26.0) 583 (74.0)  
 College Graduate 107 (23.6) 347 (76.4)  
    
Income <15,000 31 (24.0) 98 (76.0) 0.17 
 15000-50000 191 (27.4) 506 (72.6)  
 ≥ 50000 98 (21.8) 351 (78.2)  
    
Recency of 
Pregnancy  
Nulliparous 65 (19.4) 270 (80.6) 0.84 
5+ yrs 209 (29.3) 505 (70.7)  
 2 - < 5 yrs 33 (23.1) 110 (76.9)  
 < 2 yrs 16 (17.6) 75 (82.4)  
    
Smoking Never 212 (32.6) 439 (67.4) <0.0001 
 Former 52 (18.6) 227 (81.4)  
 Current 60 (16.9) 294 (83.1)  
    
BMI quartile 1st 70 (22.0) 248 (78.0) 0.0002 
  2nd 59 (18.7) 256 (81.3)  
  3rd 83 (25.9) 237 (74.1)  
  4th 106 (33.0) 215 (67.0)  
1. Non-drinkers includes those who did not drink during the 5 year period, as well as those who 
did not drink in their lifetime 
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Table 3. Risk of Dying after Breast Cancer in Relation to Level of Alcohol Consumption 
among Women Diagnosed with Breast Cancer under 45 Years of Age from 1983 to 1992  
* statistically significant HR 
** due to rounding, p-value < 0.05 
1 adjusted for age, diagnosis year, mammography 
2 Non-drinkers include those who did not drink during the 5 year period, as well as those who did 
not drink in their lifetime 
Average Weekly 
Alcohol Consumption 
as drinks per week 
Alive Dead HR1 95% CI 
5 Years Prior to 
     Diagnosis 
    
Non-drinkers2 216 (67.1) 106 (32.7) 1.0 (ref)   
Drinkers 701 (73.4) 254 (26.6) 0.7* 0.5 0.9 
     >0 to <3 370 (72.0) 144 (28.0) 0.7* 0.6 1.0** 
     3 to <7 150 (78.1) 42 (21.9) 0.6* 0.4 0.8 
     ≥7  181 (72.7) 68 (27.3) 0.7* 0.5 0.9 
     
      Wine drinkers     
Non-wine drinkers 307 (67.6) 147 (32.4) 1.0 (ref)   
Wine drinkers 615 (73.9) 217 (26.1) 0.7* 0.6 0.9 
     >0 to <3 430 (72.9) 160 (27.1) 0.8 0.6 1.1 
     3 to <7 100 (75.8) 32 (24.2) 0.7 0.5 1.1 
     ≥7  85 (77.3) 25 (22.7) 0.7 0.5 1.1 
     
      Beer drinkers     
Non-beer drinkers 503 (70.8) 207 (29.2) 1.0 (ref)   
Beer drinkers 412 (72.5) 156 (27.5) 0.9 0.7 1.1 
     >0 to <3 309 (72.7) 116 (27.3) 0.9 0.7 1.1 
     3 to <7 55 (75.3) 18 (24.7) 0.8 0.5 1.2 
     ≥7  48 (68.8) 22 (31.4) 1.0 0.6 1.5 
     
      Liquor drinker     
Non-liquor drinkers 353 (70.9) 145 (29.1) 1.0 (ref)   
Liquor drinkers 567 (72.1) 219 (27.9) 0.9 0.7 1.1 
     >0 to <3 460 (72.3) 176 (27.7) 0.9 0.7 1.1 
     3 to <7 53 (68.0) 25 (32.0) 1.1 0.6 1.5 
     ≥7  54 (75.0) 18 (25.0) 0.8 0.5 1.2 
     
Over the Lifetime      
Never Drinkers 160 (65.8) 83 (34.2) 1.0 (ref)   
Ever Drinkers 756 (73.0) 280 (27.0) 0.7* 0.5 0.8 
     >0 to <3  432 (74.0) 152 (26.0) 0.6* 0.5 0.8 
     3 to <7 178 (70.6) 74 (29.4) 0.7* 0.5 1.0** 
     ≥7  146 (73.0) 54 (27.0) 0.6* 0.5 0.9 
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Table 4.  Relationship of Average Weekly Alcohol Consumption in 5 Years Prior to Diagnosis to 
Tumor Characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alcohol Consumption1 Tumor Characteristic OR (95% CI)2 
 ER   
 Positive Negative OR 
Non-drinkers 148 (27.7) 92 (25.1) 1.0 (ref) 
Drinkers 386 (72.3) 274 (74.9) 1.1 (0.8-1.4) 
 PR   
 Positive Negative  
Non-drinkers 150 (27.6) 89 (25.1) 1.0 (ref) 
Drinkers 394 (72.4) 266 (74.9) 1.0 (0.7-1.4) 
 Tumor Necrosis   
 None-Intermediate High  
Non-drinkers 222 (25.5) 35 (33.3) 1.0 (ref) 
Drinkers 650 (74.5) 70 (66.7) 0.6* (0.4-1.0**) 
 Ki-67   
 Low High  
Non-drinkers 140 (26.0) 98 (27.8) 1.0 (ref) 
Drinkers 399 (74.0) 255 (72.2) 0.9 (0.7-1.3) 
 BCL-2   
 High Low  
Non-drinkers 109 (28.9) 128 (24.8) 1.0 (ref) 
Drinkers 266 (70.9) 389 (75.2) 1.3 (0.9-1.7) 
  P53   
 Negative Positive  
Non-drinkers 132 (24.6) 105 (29.3) 1.0 (ref) 
Drinkers 405 (75.4) 254 (70.8) 0.7 (0.5-1.0) 
 % S phase   
 Low High  
Non-drinkers 80 (24.6) 92 (28.1) 1.0 (ref) 
Drinkers 245 (75.4) 235 (71.9) 0.8 (0.5-1.1) 
 Stage   
 Local Regional/Distant  
Non-drinkers 183 (24.9) 137 (25.7) 1.0 (ref) 
Drinkers 551 (75.1) 396 (74.3) 1.1 (0.8-1.4) 
 Grade   
 Low/Intermediate High  
Non-drinkers 137 (25.3) 116 (26.9) 1.0 (ref) 
Drinkers 405 (74.7) 315 (73.1) 1.2 (0.9-1.6) 
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* statistically significant OR 
** due to rounding, p-value < 0.05 
1 during the 5 year period prior to diagnosis; non-drinkers include those who did not drink during 
the 5 year period 
2 adjusted for age, diagnosis year, smoking status  
 
 
